Lymphoma

"I can’t make [treatment] decisions for you, but I can give you realistic expectations," said Herbert Lepor, MD, of NYU Langone Health.

A multidisciplinary panel discussed second-line CAR T-cell candidacy, real-world referral barriers, and the management of delayed toxicities in DLBCL.

Among evaluable patients with B-cell NHL from the dose-escalation portion of the trial without CNS involvement, all CRs were sustained through 6 months.

Nikesh Shah, MD, discussed the specific factors that shape the choice between a bispecific and CAR T-cell therapy in follicular lymphoma.

Carlos Silva Rondon, MD, of Moffitt Cancer Center discussed factors guiding selection between CAR T therapy or bispecific antibodies in follicular lymphoma.

In a phase 1 trial, englumafusp alfa plus glofitamab produced a 68.7% overall response rate in heavily pretreated aggressive B-cell non-Hodgkin lymphoma.

The European Commission approved epcoritamab/R2 for adult patients with relapsed/refractory follicular lymphoma based on the phase 3 EPCORE FL-1 data.

Experts focused on lymphoma cellular therapy convened to discuss CAR T-cell candidacy and practical barriers to access for patients with DLBCL.

Full phase 3 MANGROVE trial data will be presented at an upcoming medical meeting, with global regulatory submissions planned for the second half of 2026.

“[Epcoritamab/R2] is a good option for [patients] at first relapse or even further, even if they are very high risk,” said Benoit Tessoulin, MD, PhD.

In this Satellite Session, experts convened to discuss CAR T-cell candidacy among patients across a range of large B-cell lymphoma disease states.

The safety profile of epcoritamab when added to lenalidomide was consistent with the known profiles of each individual agent among this DLBCL population.

Experts map DLBCL CAR‑T from early referral and bridging therapy to managing CRS, ICANS, and survivorship challenges in community practice.

Guilherme Fleury Perini, MD, PhD, discussed KEYFORM-008 findings on favezelimab/pembrolizumab vs chemotherapy in PD-1–refractory classic Hodgkin lymphoma.

Findings from the phase 2 MOR208C203 trial and phase 1b/2 INCMOR 0208-102 trial support the Japanese regulatory decision for tafasitamab in DLBCL.

“I love that our field is taking an ambitious swing at how best to take care of patients who are older and less fit with large cell lymphoma,” said Matthew Matasar, MD, chief in the division of Blood Disorders, Rutgers Cancer Institute/Jack & Sheryl Morris Cancer Center, and professor of medicine at Rutgers Robert Wood Johnson Medical School.

Findings from the phase 3 SUNMO trial support the regulatory decision regarding the mosunetuzumab-based regimen for this relapsed/refractory population.

The investigators concluded that the impact of autologous stem cell transplantation with ibrutinib cannot be determined vs ibrutinib alone.

Among 3-to-25-year-old patients with slow, early responses to chemotherapy with newly diagnosed classic Hodgkin lymphoma, pembrolizumab showed an ORR of 98%.

Emmanuel Bachy, MD, PhD, shared data from a phase 1b study evaluating subcutaneous mosunetuzumab plus lenalidomide in untreated follicular lymphoma.

Brentuximab vedotin plus ifosfamide, carboplatin, and etoposide conferred significantly increased toxicity vs 2 other chemotherapy-containing regimens.

Updated phase 1/1b BGB-11417-101 trial data showed sonrotoclax 320 mg plus zanubrutinib achieved uMRD4 rates exceeding 90% in treatment-naive CLL/SLL.

Emmanuel Bachy, MD, PhD, highlighted high efficacy, durable responses, and a favorable adverse effect profile in follicular lymphoma with high tumor burden.

The safety profile of the CAR T-cell product in the real world was consistent with that observed in the TRANSCEND MCL study.

No new safety signals were observed with the LAG-3 inhibitor-based therapy among patients with relapsed/refractory classic Hodgkin lymphoma.